Heart health study for people with osteogenesis imperfecta
Part of Bones, joints & muscles, Genetic & congenital, Skin clinical trials.
This study looks at heart structure and function in children and adults with osteogenesis imperfecta (OI), a condition that affects bones. Researchers want to understand how OI may impact the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with osteogenesis imperfecta (OI) by a doctor using the modified Sillence classification.
- You are scheduled for a genetic consultation at the Rare Skeletal Diseases Unit of the IRCCS Rizzoli Orthopaedic Institute (IOR).
- You are willing to have heart exams and other tests done at the IOR.
- You do not have a current respiratory infection (like a cold, flu, or chest infection) at the time of your visit.
- You do not have a cognitive impairment that would make it hard for you to follow instructions or complete the tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry, meaning it collects health information about people with osteogenesis imperfecta (OI) to better understand the condition. It may help researchers learn what care works best and how OI varies from person to person.
This study uses a new ultrasound technology called REMS to check bone health in children aged 5 to 18 who have conditions that weaken bones. It may help find low bone density without radiation.
This study follows people with osteogenesis imperfecta (OI) to better understand how it affects bones and related issues over time. It may help doctors learn which features and genetic changes predict problems, and guide future care.
This study checks how well the inner ear and balance system work in children and young adults with osteogenesis imperfecta (OI). The goal is to better understand hearing and balance issues that can affect daily life.
This trial tests a cell-based treatment to improve bone strength in children with the most severe type of osteogenesis imperfecta (brittle bone disease). If you qualify, it may help slow bone weakening and support growth.
This study tests a new medicine called AGA2115 in adults and teenagers with osteogenesis imperfecta (brittle bone disease). The trial aims to find the right dose and see if it can strengthen bones and reduce fracture risk.
Hear when a new Osteogenesis Imperfecta trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.